Synthesis and immunomodulatory activity of [60]fullerene-tuftsin conjugates

Biomaterials

Volumn 32, Issue 36, 2011, Pages 9940-9949

  Xu, Yingying ^a   Zhu, Jiadan ^a   Xiang, Kun ^a   Li, Yuankai ^a   Sun, Ronghua ^a   Ma, Jie ^b   Sun, Hongfang ^a   Liu, Yuanfang ^a,c  

^a PEKING UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

^c SHANGHAI UNIVERSITY   (China)

Author keywords

Chemotaxis; Fullerene C 60; MHC II; Peritoneal macrophages; Phagocytosis; Tuftsin

Indexed keywords

CHEMOTAXIS; FULLERENE C 60; MHC II; PERITONEAL MACROPHAGE; PHAGOCYTOSIS; TUFTSIN;

AMINO ACIDS; ANTIGEN-ANTIBODY REACTIONS; BIOCHEMISTRY; ENZYMATIC HYDROLYSIS; MACROPHAGES;

FULLERENES;

CYTOSOL AMINOPEPTIDASE; FULLERENE C60; FULLERENE DERIVATIVE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUFTSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMOTAXIS; CONJUGATE; CONTROLLED STUDY; HYDROLYSIS; IMMUNOMODULATION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; ANIMALS; CELL SURVIVAL; CHEMOTACTIC FACTORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; FLOW CYTOMETRY; FLUORESCENCE; FULLERENES; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOLOGIC FACTORS; LEUCYL AMINOPEPTIDASE; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PHAGOCYTOSIS; PROTEIN STABILITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; TUFTSIN;

MURINAE;

EID: 80054057031     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.09.022     Document Type: Article

References (35)

1. Tabata Y., Ikada Y. Biological functions of fullerene. Pure Appl Chem 1999, 71(11):2047-2053.
2. Friedman S.H., De Camp D.L., Sijbesma R.P., Srdanov G., Wudl F., Kenyon G.L. Inhibition of the HIV-1 protease by fullerene derivatives: model building studies and experimental verification. J Am Chem Soc 1993, 115(15):6506-6509.
3. Tokuyama H., Yamago S., Nakamura E., Shiraki T., Sugiura Y. Photoinduced biochemical activity of fullerene carboxylic acid. J Am Chem Soc 1993, 5(15):7918-7919.
4. 60 and water-soluble fullerene derivatives as antioxidants against radical-initiated lipid peroxidation. J Med Chem 1999, 42(22):4614-4620.
5. Yang S.T., Wang H.F., Guo L., Gao Y., Liu Y.F., Cao A.N. Interaction of fullerenol with lysozyme investigated by experimental and computational approaches. Nanotechnology 2008, 19(1):395101-395108.
6. Foley S., Crowley C., Smaihi M., Bonfils C., Erlanger B.F., Seta P., et al. Cellular localisation of a water-soluble fullerene derivative. Biochem Biophys Res Commun 2002, 294(1):116-119.
7. Zakharian T.Y., Seryshev A., Sitharaman B., Gilbert B.E., Knight V., Wilson L.J. A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture. J Am Chem Soc 2005, 127(36):12508-12509.
8. Lu F.S., Haque S.A., Yang S.T., Luo P.G., Gu L.R., Kitaygorodskiy A., et al. Aqueous compatible fullerene-doxorubicin conjugates. J Phys Chem C 2009, 113(41):17768-17773.
9. Chen B.X., Wilson S.R., Das M., Coughlin D.J., Erlanger B.F. Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics. Proc Nat Acad Sci USA 1998, 95(18):10809-10813.
10. 60 and fullerene black on immuno-functions of macrophages. Fullerene Sci Technol 1996, 4(5):1073-1085.
11. Tsao N., Kanakamma P.P., Luh T.Y., Chou C.K., Lei H.Y. Inhibition of Escherichia coli-induced meningitis by carboxyfullerene. Antimicrob Agents Chemother 1999, 43(9):2273-2277.
12. 20 nanoparticles. Nanotechnology 2009, 20(41):415102-415111.
13. Masalova O.V., Shepelev A.V., Atanadze S.N., Parnes Z.N., Romanova V.S., Vol'pina O.M., et al. Immunostimulating action of water soluble fullerene derivatives as perspective adjuvants for new generation vaccine. Dokl Akad Nauk 1999, 369(3):411-413.
14. x. Small 2008, 4(8):1168-1175.
15. Siemion I.Z., Kluczy A. Tuftsin: on the 30-year anniversary of Victor Najjar's discovery. Peptides 1999, 20(5):645-674.
16. Bump N.J., Najjar V.A., Reichler J. The characteristics of purified HL60 tuftsin receptors. Mol Cell Biochem 1990, 92(1):77-84.
17. Fridkin M., Najjar V.A. Tuftsin: its chemistry, biology, and clinical potential. Crit Rev Biochem Mol Biol 1989, 24(1):1-40.
18. x in mice. Nanopart Res 2006, 8(1):53-63.
19. Pellarini F., Pantarotto D., Da Ros T., Giangaspero A., Tossi A., Prato M. A novel [60]fullerene amino acid for use in solid-phase peptide synthesis. Org Lett 2001, 3(12):1845-1848.
20. Ichinose M., Hara N., Sawada M., Maeno T. A flow cytometric assay reveals an enhancement of phagocytosis by platelet activating factor in murine peritoneal macrophages. Cell Immun 1994, 156(2):508-518.
21. Terashima M., Hara N., Badruzzaman M., Shimoyama M., Tsuchiya M. ADP-ribosylation of tuftsin suppresses its receptor-binding capacity and phagocytosis-stimulating activity to murine peritoneal macrophages. FEBS Lett 1997, 412(1):227-232.
22. Jia G., Wang H.F., Yan L., Wang X., Pei R.J., Yan T., et al. Cytotoxicity of carbon nanomaterials: single-wall nanotube, multi-wall nanotube, and fullerene. Environ Sci Technol 2005, 39(5):1378-1383.
23. Sun R.H., Gao P., Chen L., Ma D.L., Wang J.M., Oppenheim J.J., et al. Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. Cancer Res 2005, 65(4):1433-1441.
24. Pantarotto D., Bianco A., Pellarini F., Tossi A., Giangaspero A., Zelezetsky I., et al. Solid-phase synthesis of fullerene-peptides. J Am Chem Soc 2002, 124(42):12543-12549.
25. Nishioka K., Constantopoulos A., Satoh P., Mitchell W., Najjar V.A. Characteristics and isolation of the phagocytosis-stimulating peptide, tuftsin. Biochim Biophys Acta 1973, 310(1):217-229.
26. Fridkin M., Stabinsky Y., Zakuth V., Spirer Z. Tuftsin and some analogs: synthesis and interaction with human polymorphonuclear leukocytes. Biochim Biophys Acta 1977, 496(1):203-211.
27. Nishioka K., Obeyesekere N.U., McMurry J.S. Enhanced phagocytosis activity of cyclic analogs of tuftsin. Biochem Pharm 1995, 49(5):735-738.
28. Babcock G.F., Amoscato A.A., Nishioka K. Effect of tuftsin on the migration, chemotaxis, and differentiation of macrophages and granulocytes. Ann N Y Acad Sci 1983, 419(12):64-74.
29. Gershonov E., Granoth R., Tzehoval E., Gaoni Y., Fridkin M. 1-Aminocyclobutanecarboxylic acid derivatives as novel structural elements in bioactive peptides: application to tuftsin analogs. J Med Chem 1996, 39(24):4833-4843.
30. Yang J.Z., Alemany L.B., Driver J., Hartgerink J.D., Barron A.R. Fullerene-derivatized amino acids: synthesis, characterization, antioxidant properties, and solid-phase peptide synthesis. Chem Eur J 2007, 13(9):2530-2545.
31. Innocenti A., Durdagi S., Doostdar N., Strom T.A., Barron A., Supuran C. Nanoscale enzyme inhibitors: fullerenes inhibit carbonic anhydrase by occluding the active site entrance. Bioorg Med Chem 2010, 18(8):2822-2828.
32. Pastorin G., Marchesan S., Hoebeke J., Da Ros T., Ehret-Sabatier L., Briand J.P., et al. Design and activity of cationic fullerene derivatives as inhibitors of acetylcholinesterase. Org Biomol Chem 2006, 4(13):2556-2562.
33. Powell J.J., Faria N., Thomas-McKay E., Pele L.C. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 2010, 34(3):J226-J233.
34. Singh M., Chakrapani A., O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007, 6(5):797-808.
35. Peek L.J., Middaugh C.R., Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliver Rev 2008, 60(8):915-928.